Literature DB >> 10389125

Antagonism of the renin-angiotensin-aldosterone system and collagen metabolism in cardiac fibroblasts.

P Lijnen1, V Petrov.   

Abstract

The renin-angiotensin-aldosterone system has emerged as a potential candidate for the accumulation of collagen in cardiac fibroblasts. The traditional renin-angiotensin-aldosterone system can be considered a system in which circulating angiotensin II or aldosterone is delivered to target tissue or cells. However, an independent local renin-angiotensin system has also been described in cardiac cells and evidence has been accumulated for autocrine and/or paracrine pathways by which biological actions of angiotensin II can be mediated. These actions of angiotensin II are primarily mediated through angiotensin II receptors of the subtype I (AT1). When evaluating the effects of angiotensin II in situ, changes in circulating levels and local production both have to be taken into account. Functional angiotensin II receptors have been documented in cardiac fibroblasts although the presence of aldosterone receptors in cardiac fibroblasts is obscure, and the expression of mRNA for mineralocorticoid receptors in cardiac fibroblasts has been described. In vitro, angiotensin II increased cardiac fibroblast-mediated collagen synthesis and mRNA levels of collagen type I, type III, pro-alpha 1 (I) collagen, pro-alpha 1 (III) collagen and fibronectin, and inhibited matrix metalloproteinase I activity. The ability of angiotensin II to induce collagen synthesis and expression of collagen in cardiac fibroblasts may be mediated by an increase in transforming growth factor-beta 1 in an autocrine/paracrine fashion. The angiotensin II-stimulated secretion and expression of collagen was completely abolished by AT1 receptor antagonism, but not affected by AT2 receptor antagonism. The discordant findings that have been reported concerning the in vitro effect of aldosterone on collagen synthesis in cardiac fibroblasts can at least partly be attributed to differences in methodology such as the use of the total population or a sub-population of cardiac fibroblasts. In vivo, chronic infusion of angiotensin II or aldosterone increased the collagen volume fraction in the ventricles. Angiotensin-converting enzyme (ACE) inhibition and AT1 receptor antagonism, but not AT2 receptor antagonism, reduced collagen deposition in the myocardium in spontaneously hypertensive rats. The cardioprotective mechanism of action of ACE inhibitors can be attributed to local blockade of the formation of angiotensin II, to the degradation of bradykinin or to the release of nitric oxide and/or eicosanoids. Angiotensin-converting enzyme inhibitors also reduced collagen deposition in rat myocardium following myocardial infarction suggesting that collagen deposition may in part result from mechanisms other than through AT1 receptors. However, further research is necessary to unravel the various mechanisms involved in the action of angiotensin-converting enzyme inhibitors or of AT1 receptor antagonists on collagen deposition in the myocardium.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10389125     DOI: 10.1358/mf.1999.21.3.534832

Source DB:  PubMed          Journal:  Methods Find Exp Clin Pharmacol        ISSN: 0379-0355


  7 in total

1.  Aliskiren and valsartan mediate left ventricular remodeling post-myocardial infarction in mice through MMP-9 effects.

Authors:  Trevi A Ramirez; Rugmani Padmanabhan Iyer; Omid Ghasemi; Elizabeth F Lopez; Daniel B Levin; Jianhua Zhang; Rogelio Zamilpa; Youn-Min Chou; Yu-Fang Jin; Merry L Lindsey
Journal:  J Mol Cell Cardiol       Date:  2014-04-23       Impact factor: 5.000

Review 2.  Diastolic heart failure in the elderly and the potential role of aldosterone antagonists.

Authors:  Ashwani Kumar; Gary Meyerrose; Vineeta Sood; Chanwit Roongsritong
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

Review 3.  Effect of MR blockade on collagen formation and cardiovascular disease with a specific emphasis on heart failure.

Authors:  Faiez Zannad; Anca Radauceanu
Journal:  Heart Fail Rev       Date:  2005-01       Impact factor: 4.214

4.  Proteomic Analysis of Effects of Spironolactone in Heart Failure With Preserved Ejection Fraction.

Authors:  Ali Javaheri; Ahmed Diab; Lei Zhao; Chenao Qian; Jordana B Cohen; Payman Zamani; Anupam Kumar; Zhaoqing Wang; Christina Ebert; Joseph Maranville; Erika Kvikstad; Michael Basso; Vanessa van Empel; A Mark Richards; Robert N Doughty; Ernst Rietzschel; Karl Kammerhoff; Joseph Gogain; Peter Schafer; Dietmar A Seiffert; David A Gordon; Francisco Ramirez-Valle; Douglas L Mann; Thomas P Cappola; Julio A Chirinos
Journal:  Circ Heart Fail       Date:  2022-08-09       Impact factor: 10.447

5.  Spironolactone attenuates experimental uremic cardiomyopathy by antagonizing marinobufagenin.

Authors:  Jiang Tian; Amjad Shidyak; Sankaridrug M Periyasamy; Steven Haller; Mohamed Taleb; Nasser El-Okdi; Jihad Elkareh; Shalini Gupta; Sabry Gohara; Olga V Fedorova; Christopher J Cooper; Zijian Xie; Deepak Malhotra; Alexei Y Bagrov; Joseph I Shapiro
Journal:  Hypertension       Date:  2009-11-02       Impact factor: 10.190

6.  Effect of an ACE inhibitor and an AT1 receptor antagonist on cardiac hypertrophy.

Authors:  Chihiro Shikata; Atsushi Takeda; Nobuakira Takeda
Journal:  Mol Cell Biochem       Date:  2003-06       Impact factor: 3.396

7.  Treatment with spironolactone for 24 weeks decreases the level of matrix metalloproteinases and improves cardiac function in patients with chronic heart failure of ischemic etiology.

Authors:  M J Li; C X Huang; E Okello; T Yanhong; S Mohamed
Journal:  Can J Cardiol       Date:  2009-09       Impact factor: 5.223

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.